

North Central Cancer Treatment Group

N027D A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation
Therapy in Glioblastoma Multiforme

Revised Status Change – April 4, 2008

NOTICE OF STATUS CHANGE

As of Addendum 3, this study reopens. Arm A reopens at dose level 1 (50 mg/wk) for CCI-779. Addendum 3 also added Arm B with doses already determined. New enrollment will not be allowed until IRB approval of Addendum 3 is obtained.

Please retain this notice with the protocol.